NCT07174843View on ClinicalTrials.gov

An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

December 31, 2027

Conditions
Idiopathic Inflammatory Myopathies(IIM)Immune Thrombocytopenia(ITP)Systemic Lupus Erythematosus(SLE)
Interventions
BIOLOGICAL

CD19/CD22/BCMA CAR-T cells(BZE2204)

"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of BZE2204 CAR T cells.~On day0 subjects will receive a single dose BZE2204 CAR T cells by intravenous (IV) injection."

Trial Locations (1)

200240

RECRUITING

Shanghai Mengchao Cancer Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Cell Therapy Group Co.,Ltd

INDUSTRY